Share price of Universal Biosensors (ASX:UBI) noticed a surge up to 9.3%, reaching A$0.295.

If the gain holds steady, it will be the best performing day for the company since September 20.

This catalytic jump comes as the biosensor manufacturer announced the much-awaited approval for the sale of ‘Xprecia Prime 4U’, a coagulation analyzer, to patients for self-testing in Europe.

The official approval comes in the form of an ‘EU Technical Documentation Assessment Certificate’, graciously issued by TÜV SÜD Product Service GmbH.

The positive news boosted the stock to its highest level since September 21.

A massive number of shares changed hands today, reaching 219,686, vastly surpassing the usual 30-day average volume of 64,644.

Amassing an impressive 20% rise Year-To-Date, as accounted for at the last close.

Universal Biosensors is known for developing, manufacturing and selling biosensors for the healthcare industry.